Discovery of Novel Broad-Spectrum Coronavirus Mpro Inhibitors

新型广谱冠状病毒 Mpro 抑制剂的发现

• 批准号: 10845861
• 负责人: Julien Papillon
• 金额: $ 78.52万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-16 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10845861
• 关键词: 2019-nCoV; Antiviral Agents; Binding Proteins; Biochemical; Biological Assay; COVID-19 outbreak; COVID-19 pandemic; Canis familiaris; Cardiovascular system; Caspase; Cell Line; Central Nervous System; Clinic; Clinical Research; Clinical Trials; Coronavirus; Cytochrome P450; Development; Disease Outbreaks; Dose; Drug Interactions; Ensure; Epithelial Cells; Evolution; Foundations; Funding; Future; Generations; Goals; Guidelines; Hamsters; Human; In Vitro; Individual; Infection; International; Lead; Metabolism; Middle East Respiratory Syndrome; Modeling; Monitor; Monkeys; Mus; Mutation; Oral; Pathogenicity; Peptide Hydrolases; Pharmaceutical Chemistry; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacology; Phototoxicity; Plasma Proteins; Property; Protease Inhibitor; Proteins; Rattus; Recovery; Resistance; Safety; Selection Criteria; Testing; Toxicology; Vaccines; Variant; Viral; Viral Pathogenesis; Virus; Virus Replication; airway epithelium; attenuation; clinical candidate; clinical development; coronavirus pandemic; experimental study; fitness test; future pandemic; genotoxicity; good laboratory practice; human coronavirus; in vitro Assay; in vivo; inhibitor; lead optimization; lead series; minimal risk; mutant; novel; novel coronavirus; pandemic preparedness; preclinical development; programs; resistance mutation; respiratory; success; tool; variant of interest; zoonotic coronavirus

PROJECT 1 - ABSTRACT The goal of this project is to discover novel broad-spectrum coronavirus main protease (Mpro) inhibitors. We have already obtained promising first-generation Mpro inhibitors with desired potency and drug-like properties. The first-generation Mpro inhibitors are rapidly progressing to clinical development. In the current application, we will capitalize the success of the first-generation inhibitor to develop the second-generation inhibitor. In anticipation of future coronavirus emergence, the second-generation inhibitor will have (i) activities against viruses resistant to the first-generation inhibitor and (ii) a broader coverage against different coronaviruses. To achieve this goal, we will pursue three aims: (i) identify the antiviral spectrum of the first-generation Mpro inhibitor and evaluate the potential to induce resistance; (ii) discover and optimize a second-generation novel broad- spectrum Mpro inhibitor to anticipate potential resistance and future pandemics; and (iii) advance our second- generation broad-spectrum coronavirus Mpro inhibitor through preclinical development to deliver an IND-ready clinical candidate.

项目1 -摘要